STOCK TITAN

Sonoma Pharmaceuticals Inc. - SNOA STOCK NEWS

Welcome to our dedicated news page for Sonoma Pharmaceuticals (Ticker: SNOA), a resource for investors and traders seeking the latest updates and insights on Sonoma Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sonoma Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sonoma Pharmaceuticals's position in the market.

Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. has announced the pricing of its public offering of 8,500,000 shares of common stock at $0.20 per share, expecting gross proceeds of approximately $1.7 million. The offering is set to close on October 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-48.65%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Sonoma Pharmaceuticals, Inc. announced financial results for its first fiscal quarter ended June 30, 2023. Revenue increased 6% compared to the same period last year, excluding a one-time event. Margins remained consistent year over year. Sonoma managed cash tightly, using only $0.3 million in its first fiscal quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
Rhea-AI Summary
Sonoma Pharmaceuticals announces the appointment of Dr. Hye Jin Chung to its Scientific Advisory Board. Dr. Chung's expertise in dermatology will contribute to the company's research and development efforts in the field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.54%
Tags
-
Rhea-AI Summary
Sonoma Pharmaceuticals announces a new application for its Microcyn® technology-based stabilized hypochlorous acid products. The intraoperative pulse lavage irrigation treatment can replace IV bags in surgical procedures, providing a non-toxic solution to prevent infection and improve healing time. The product is cost competitive with IV bags and is expected to be ready for commercial use in Europe in September 2023 and in the U.S. in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
44.33%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.26%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
Sonoma Pharmaceuticals Inc.

Nasdaq:SNOA

SNOA Rankings

SNOA Stock Data

2.74M
15.35M
1.56%
1.95%
0.19%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
Woodstock

About SNOA

sonoma pharmaceuticals, inc., develops and produces stabilized hypochlorous acid (hocl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the united states and internationally. the company offers epicyn, an antimicrobial facial cleanser; levicyn, a hypochlorous acid (hocl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; sebuderm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and ceramax, a lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as loyon for the management of skin scal